Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Petra Hoffknecht"'
Autor:
Petros Christopoulos, Franziska Herster, Petra Hoffknecht, Markus Falk, Markus Tiemann, Hans-Georg Kopp, Andre Althoff, Anja Stammberger, Eckart Laack
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). However, 10–20% of patients with EGFRm+ NSCLC have u
Externí odkaz:
https://doaj.org/article/d9d647cfc3ce49f18e8635c29acf8bc3
Autor:
Frank Griesinger, MD, PhD, Wilfried E.E. Eberhardt, MD, PhD, Wolfgang M. Brueckl, MD, PhD, Horst-Dieter Hummel, MD, PhD, Bastian Jaeschke, MD, Jens Kern, MD, Claas Wesseler, MD, Martina Jänicke, PdD, Annette Fleitz, PhD, Stefan Zacharias, PhD, Annette Hipper, PhD, Annika Groth, MD, PhD, Wilko Weichert, MD, PhD, Steffen Dörfel, Volker Petersen, MD, Jan Schröder, MD, Jochen Wilke, MD, Martin Sebastian, MD, Michael Thomas, MD, PhD, Juliana Ababei, Jürgen Alt, Andreas Ammon, Jürgen Anhuf, Ivo Azeh, Stefan Bauer, Dirk Behringer, Winfried Berger, Christiane Bernhardt, Mathias Bertram, Michael Boesche, Sabine Bohnet, Harald-Robert Bruch, Wolfgang Brückl, Ulrike Burkhard-Meier, Petros Christopoulos, Klaus-Ulrich Däßler, Maike de Wit, Tobias Dechow, Reinhard Depenbusch, Lutz Dietze, Markus Dommach, Wilfried Eberhardt, Corinna Elender, Wolfgang Elsel, Till-Oliver Emde, Martin Faehling, Thomas Fietz, Jürgen R. Fischer, Dimitri Flieger, Anke Freidt, Werner Freier, Christian Frenzel, Florian Fuchs, Roswitha Fuchs, Tobias Gaska, Wolfgang Gleiber, Christian Grah, Frank Griesinger, Christian Grohé, Matthias Groschek, Björn Güldenzoph, Andreas Günther, Siegfried Haas, Matthias Hackenthal, Volker Hagen, Lars Hahn, Verena Hannig Carla, Richard Hansen, Hanns-Detlev Harich, Monika Heilmann, Kathrin Heinrich, Christiane Hering-Schubert, Jörg Heßling, Petra Hoffknecht, Patricia Hortig, Gerdt Hübner, Horst-Dieter Hummel, Ulrich Hutzschenreuter, Thomas Illmer, Georg Innig, Bastian Jaeschke, Christian Junghanß, Ulrich Kaiser, Haytham Kamal, Kato Kambartel, Jens Kern, Martin Kimmich, Dorothea Kingreen, Heinz Kirchen, Martine Klausmann, Ortwin Klein, Konrad Kokowski, Wolfgang Körber, Cornelius Kortsik, Dirk Koschel, Benoit Krämer, Beate Krammer-Steiner, Eckart Laack, Christof Lamberti, Rumo David Leistner, Christoph Losem, Andreas Lück, Christoph Maintz, Kerstin Martin, Dirk Medgenberg, Martin Metzenmacher, Christian Meyer zum Büschenfelde, Philipp Meyn, Enno Moorahrend, Annette Müller, Lothar Müller, Michael Neise, Holger Nückel, Arnd Nusch, Tobias Overbeck, Henning Pelz, Volker Petersen, Bettina Peuser, Margarete Plath, Winfried J. Randerath, Jacqueline Rauh, Martin Reck, Dietmar Reichert, Niels Reinmuth, Marcel Reiser, Roland Repp, Daniel Reschke, Achim Rittmeyer, Yolanda Rodemer, Sandra Sackmann, Parvis Sadjadian, Reiner Sandner, Annette Sauer, Harald Schäfer, Christoph Schaudt, Rudolf Schlag, Burkhard Schmidt, Stephan Schmitz, Jan Schröder, Michael Schroeder, Mathias Schulze, Christian Schumann, Wolfgang Schütte, Martin Schwaiblmair, Florian Schwindt Peter, Martin Sebastian, Bernd Seese, Gernot Seipelt, Thomas Sorgenfrei, Johannes Steiff, Heike Steiniger, Tanja Trarbach, Amanda Tufman, Jens Uhlig, Ursula Vehling-Kaiser, Eyck von der Heyde, Ulla von Verschuer, Cornelius Waller, Thomas Wehler, Georg Weißenborn, Florian Weißinger, Martin Wermke, Claas Wesseler, Jörg Wiegand, Stefan Wilhelm, Jochen Wilke, Mark-Oliver Zahn, Matthias Zaiss, Matthias Zeth
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100626- (2024)
Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNS
Externí odkaz:
https://doaj.org/article/193c505adea04fdda590997c6e7e69c0
Autor:
Balázs Jóri, Christine Vössing, Judith Pirngruber, Eva Maria Willing, Kathrin Arndt, Markus Falk, Markus Tiemann, Lukas C. Heukamp, Petra Hoffknecht
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 8805-8814 (2023)
EGFR-mutant lung cancers develop a wide range of potential resistance alterations under therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET amplification ranks among the most common acquired resistance alterations and is
Externí odkaz:
https://doaj.org/article/4e628e918b044546be96ca670e533995
Autor:
Evgenii Shumilov, Lena Aperdannier, Nicole Schmidt, Christoph Szuszies, Albrecht Neesse, Petra Hoffknecht, Cyrus Khandanpour, Jan-Henrik Mikesch, Matthias Stelljes, Göran Ramin Boeckel, Phil-Robin Tepasse, Lea Reitnauer, Raphael Koch, Justin Hasenkamp, Ulrike Bacher, Simone Scheithauer, Lorenz Trümper, Norbert Schmitz, Gerald Wulf, Andrea Kerkhoff, Georg Lenz, Carolin Krekeler, Annalen Bleckmann
Publikováno v:
Cancers, Vol 14, Iss 15, p 3746 (2022)
COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analy
Externí odkaz:
https://doaj.org/article/52432a54743542dc8634583697fa4c95
Autor:
Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph
Publikováno v:
Data in Brief, Vol 34, Iss , Pp 106556- (2021)
Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.201
Externí odkaz:
https://doaj.org/article/05cec1d0dcbe40d8bb40153fc5d15af0
Autor:
Wolfgang M Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H Ficker, Eckart Laack
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 14 (2020)
Background: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was to eval
Externí odkaz:
https://doaj.org/article/cfc495dfbcf041fc93f8a04d10f6baa9
Autor:
Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, Hayat O. Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger, Markus Tiemann, Lukas C. Heukamp, Markus Falk
Publikováno v:
Cancers, Vol 13, Iss 12, p 2861 (2021)
Since 2009, several first, second, and third generation EGFR tyrosine kinase inhibitors (TKI) have been approved for targeted treatment of EGFR mutated metastatic non-small lung cancer (NSCLC). A vast majority of patients is improving quickly on trea
Externí odkaz:
https://doaj.org/article/1d706ef433cc4f37819d862bfaf7c933
Autor:
Evgenii Shumilov, Petra Hoffknecht, Raphael Koch, Rudolf Peceny, Steffen Voigt, Nicole Schmidt, Micha Peeck, Ulrike Bacher, Simone Scheithauer, Lorenz Trümper, Georg Lenz, Andrea Kerkhoff, Annalen Bleckmann
Publikováno v:
Cancers, Vol 13, Iss 12, p 2917 (2021)
Oncologists face challenges in the management of SARS-CoV-2 infections and post-SARS-CoV-2 cancer treatment. We analyzed diagnostic, clinical and post-SARS-CoV-2 scenarios in patients from three German cancer centers with RT-PCR confirmed SARS-CoV-2
Externí odkaz:
https://doaj.org/article/37c9f5805385473b97a428b088148455
Autor:
Stefanie Schatz, Markus Falk, Balázs Jóri, Hayat O. Ramdani, Stefanie Schmidt, Eva-Maria Willing, Roopika Menon, Harry J. M. Groen, Linda Diehl, Matthias Kröger, Claas Wesseler, Frank Griesinger, Petra Hoffknecht, Markus Tiemann, Lukas C. Heukamp
Publikováno v:
Cancers, Vol 12, Iss 6, p 1685 (2020)
In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC lacking targetable genetic alterations, immune checkpoint inhibiti
Externí odkaz:
https://doaj.org/article/7a4f925dc71b4832a327e67fb9075603
Autor:
Bleckmann, Evgenii Shumilov, Lena Aperdannier, Nicole Schmidt, Christoph Szuszies, Albrecht Neesse, Petra Hoffknecht, Cyrus Khandanpour, Jan-Henrik Mikesch, Matthias Stelljes, Göran Ramin Boeckel, Phil-Robin Tepasse, Lea Reitnauer, Raphael Koch, Justin Hasenkamp, Ulrike Bacher, Simone Scheithauer, Lorenz Trümper, Norbert Schmitz, Gerald Wulf, Andrea Kerkhoff, Georg Lenz, Carolin Krekeler, Annalen
Publikováno v:
Cancers; Volume 14; Issue 15; Pages: 3746
COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analy